Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
New budgeting challenges require flexible thinking. This brief guide offers strategies to adjust your plan while maintaining financial stability.
24,577 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
A high-profile Arkansas event sparked financial ripples as sponsors and donors paused amid controversy. This article ...
Planet Labs stock popped today after a standout quarter and optimism about a path to profitability. This article brea...
A new wave of small modular reactors could reshape the US power mix. This article explains why NuScale Power is catch...
Quantum computing is shaping up as the next big investment wave. This guide highlights three stocks poised to benefit...
AI stocks keep surprising investors with durable growth. Here’s a detailed, practical case for a single stock that ch...
Synopsys, a leader in chip design software, trades below its 52-week high even as revenue grows, highlighting investo...
Oil has eased from double-digit spikes as tensions with Iran ease, nudging markets toward calmer inflation expectatio...
Lyft’s leadership introduces a multi-sensor safety standard for autonomous rides, positioning safety at the center as...
A California winery cofounder launches a program to cover living costs for families affected by cancer, challenging t...
When a familiar tech name moves lower mid-session, investors want answers. This guide breaks down why intel stock dro...
BYD expands beyond China with a strong EU push, a growing factory footprint, and a multi-region strategy that could r...